Lilly Ventures,
禮來公司的第一支投資基金—禮來風險基金(Lilly Ventures, )設立于2001年,專注于北美和歐洲地區的投資。
禮來亞洲基金(Lilly Asia Ventures)設立于2008年,專注于亞洲尤其是中國地區的投資.我們也是目前中國唯一的一支由跨國制藥公司設立的投資基金。通過禮來公司這根紐帶,我們為被投資公司帶來巨大的戰略資源并提供出色的增值服務。
Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company. Our investment philosophy drives us to seek great companies with compelling life science innovations. We partner actively with the management teams of our portfolio companies to realize the potential of their technologies. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. Lilly Ventures currently has $200 million under management with a focus on the North American and European regions.
Investment Focus
Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline.
Medical Technology: targeting investments in companies focusing on the convergence of devices with pharmaceuticals or diagnostics.
Value Added Resources
ACCESS TO INDUSTRY KNOWLEDGE AND CONTACTS
Through our relationship with Eli Lilly and Company, Lilly Ventures provides our portfolio companies with access to the collective knowledge and contact base generated by Lilly's world-class scientists, experienced clinical investigators and respected sales and marketing professionals
PRODUCT INSIGHTS
Our relationship with Eli Lilly and Company greatly enhances our ability to evaluate new technologies and therapies from a customer or prospective partner perspective.
STRATEGIC RELATIONSHIPS
Our collaborations with industry experts, the venture capital industry and investment banks give us a global network of contacts to assist portfolio companies with various aspects of growing their business.